Q-omics provides the consensus-scored PCDHB14 profile across patient tissues and cancer cell-line models. PCDHB14 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PCDHB14 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PCDHB14 RNA expression shows 16,926 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight LUAD, HNSC, and TGCT as cancer lineages where PCDHB14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHB14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHB14 survival associations across molecular data types. PCDHB14 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHB14 RNA expression–survival associations across cancer types. High PCDHB14 expression shows unfavorable associations in LUAD, BLCA, KIRP and BRCA, but favorable associations in SKCM and LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for PCDHB14 RNA expression.
This table summarizes PCDHB14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PCDHB14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHB14 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, KIRP, LIHC and COAD. The HNSC box plot shows higher PCDHB14 RNA expression in tumor versus normal tissue (log2 FC = +1.237, t-test p < 0.001).
This table shows molecular features associated with PCDHB14 in patient tissues and cancer cell lines. In patient samples, PCDHB14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHB14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
